A method is reported for conjugating an analog of 4'-(aminomethyl)-4,5',8-
trimethylpsoralen to methylphophonate
oligonucleotides. This method enables the
psoralen moiety to be coupled to the
phosphonate backbone between any two desired bases in a sequence. When hybridized to a target
mRNA, the
psoralen moiety can be directed toward a
uridine base and, in turn, can undergo a photo-addition reaction with the target under UV irradiation at 365 nm. Several different non-
nucleotide-based amino-linker
reagents have been prepared for incorporation into
methylphosphonate oligonucleotides by standard phosphonamidite chemistry. In addition, an
N-hydroxysuccinimide activated
ester analog of 4'-[(3-carboxypropionamido)methyl]-4,5',8-
trimethylpsoralen has been synthesized for conjugation to the amino-linker moieties. Using this approach, we have prepared a number of
psoralen-
methylphosphonate-
oligonucleotide conjugates which are complementary to the chimeric bcr/abl
mRNA associated with
chronic myelogenous leukemia.
Solution hybridization studies with a 440-base subfragment of the bcr/abl
RNA have shown that the
psoralen moiety does not adversely affect duplex stability.
Polyacrylamide gel electrophoresis analyses have demonstrated that the
psoralen-
oligonucleotide conjugates undergo photo-addition to the
RNA in a sequence-specific manner. Optimal photo-addition occurs when the
psoralen moiety is inserted adjacent to one or more
adenine residues in the
oligonucleotide sequence, particularly between
adenine and
thymine (5'-3'). This internal labeling approach greatly increases the number of potential target sites available for photo-cross-linking experiments.